Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial

Journal of Diabetes and its Complications

Volumn 12, Issue 3, 1998, Pages 121-127

  Laudadio, Charles ^a   Sima, Anders A F ^b   Bril, V ^c   Clements, R ^c   Bell, D ^c   Charles, A ^c   Mehta, A ^c   Pillay, N ^c   Porte, D ^c   Raskin, P ^c   Schaumburg, H ^c   Sosenko, J ^c   Vinik, A ^c   Laudadio, C ^c   Aitchison, R D ^c   Arezzo, J A ^c  

^a MEDICAL CENTER OF DELAWARE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Gordon Scott Hall ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; PLACEBO; PONALRESTAT;

ARM; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ELECTROPHYSIOLOGY; HUMAN; MAJOR CLINICAL STUDY; MOTOR NERVE; MULTICENTER STUDY; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; SENSORY NERVE; SENSORY NERVE CONDUCTION; VALSALVA MANEUVER; VIBRATION SENSE;

DIABETIC NEUROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGY; HUMANS; HYPOGLYCEMIC AGENTS; MEDIAN NERVE; NEURAL CONDUCTION; NEURONS, AFFERENT; PHTHALAZINES; PLACEBOS; REFLEX; SINGLE-BLIND METHOD; SURAL NERVE; TIME FACTORS; ULNAR NERVE; VALSALVA MANEUVER;

EID: 0031747355     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(97)00074-3     Document Type: Article

References (19)

1. Laudadio C: Endpoints and clinical design for evaluating treatments for diabetic neuropathy, in Hotta N, Greene DA, Ward JD, Sima AAF, Boulton AJM (eds), Diabetic Neuropathy: New Concepts and Insights. Amsterdam, Elsevier Science BV, 1995, pp. 75-78.
2. Maser RE, Laudadio C, DeCherney S: The effects of age and diabetes mellitus on nerve function. JAGS 41:1202-1204, 1993.
3. Arezzo J, Schaumburg HH, Laudadio C: The thermal sensitivity tester: device for quantitative assessment of thermal sense in diabetic neuropathy. Diabetes 35:590-592, 1986.
4. Arezzo JC, Schaumburg HH, Laudadio C: The vibraton: A simple device for quantitative evaluation of tactile/ vibratory sense [Abstract]. Neurology 35(suppl 1):169, 1985.
5. Pfeifer MA, Weinberg CR, Cook D, Reenan A, Halter JB, Ensinck JW, Porte D Jr: Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 7:447-453, 1984.
6. Judzewitsch RG, Japan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay RH, Rubenstein AH, Porte D Jr: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 308:119-124, 1983.
7. Sima AAF, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, Greene DA: Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N Engl J Med 319:548-555, 1988.
8. Santiago JV, Sönksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B: Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function. J Diabet Complications 7:170-178, 1993.
9. Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosen I, Sonksen P: Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J Diabet Complications 6:123-130, 1992.
10. Ziegler D, Mayer P, Rathmann W, Gries FA: One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 14:63-73, 1991.
11. Boulton AJ, Levin S, Comstock J: A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33:431-437, 1990.
12. Jaspan JB, Towie VL, Maselli R, Herold K: Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism 35 (suppl 1):83-92, 1986.
13. Jaspan J, Massili R, Herold K, Bartkus C: Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor. Relief of pain and improved somatic and autonomic nerve function. Lancet 2:758-762, 1983.
14. Greene DA, Sima AAF: Effects of aldose reductase inhibitors on the progression of nerve damage. Diabetic Med 10(suppl 2):31S-32S, 1993.
15. Pfeifer MA, Peterson H, Snider H: Long-term open-label sorbinil therapy prevents the progression of diabetic neuropathy. Diabetes 37:45A, 1988.
16. Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 37:1000-1004, 1988.
17. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 18:59-82, 1995.
18. rd, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA: The Rochester diabetic neuropathy study: design criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 41:799-807, 1991.
19. Sima AAF, Albers JW, Cherian PV, Greene DA, Hohman TC, Beg M, and the Tolrestat Study Group: Correlations between structure and function in sural nerve biopsies from 336 diabetic patients. Diabetologia 36(suppl 1):A73, 1993.